1
Clinical Trials associated with Anti-CLDN-182 CAR-T (Shanghai Changhai Hospital)Clinical study of CLDN18.2-targeting chimeric antigen receptor-modified autologous T cells in advanced solid tumors with positive CLDN18.2 expression
100 Clinical Results associated with Anti-CLDN-182 CAR-T (Shanghai Changhai Hospital)
100 Translational Medicine associated with Anti-CLDN-182 CAR-T (Shanghai Changhai Hospital)
100 Patents (Medical) associated with Anti-CLDN-182 CAR-T (Shanghai Changhai Hospital)
100 Deals associated with Anti-CLDN-182 CAR-T (Shanghai Changhai Hospital)